Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

(2015) Martina Bocchetta et al.   Alzheimers & Dementia

Prevalence of Amyloid PET Positivity in Dementia Syndromes

(2015) Rik Ossenkoppele et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Use of amyloid-PET to determine cutpoints for CSF markers

(2015) Marissa D. Zwan et al.   NEUROLOGY

Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls

(2015) Niklas Mattsson et al.   JAMA Neurology

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

(2014) Stephanie J. B. Vos et al.   PLoS One

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges

(2012) Jonathan W Bartlett et al.   Biomarkers in Medicine

Disclosure of Alzheimer’s disease biomarker status in subjects with mild cognitive impairment

(2012) Pieter Jelle Visser et al.   Biomarkers in Medicine

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

(2011) Katya Rascovsky et al.   BRAIN

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

(2010) Geert De Meyer   ARCHIVES OF NEUROLOGY

Amyloid- (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

(2009) C. Mulder et al.   CLINICAL CHEMISTRY